HAIM
PETX

Hunter Associates Investment Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Hunter Associates Investment Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-19,600
Closed -$71K – 171
2019
Q1 		$71K Buy
+19,600
New +$84.9K 0.02% 159

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Hunter Associates Investment Management's PETX Position: Q2 2019 in Review

Hunter Associates Investment Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 19,600 shares — an estimated $71K sold.

Hunter Associates Investment Management first reported a position in PETX in Q1 2019 and held it in 1 quarter. The position peaked at $71K in Q1 2019. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

  • Hunter Associates Investment Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Hunter Associates Investment Management sold 19,600 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $71K.
  • Hunter Associates Investment Management first reported a position in Aratana Therapeutics, Inc. in Q1 2019 and held it in 1 quarter.
  • Hunter Associates Investment Management's Aratana Therapeutics, Inc. position peaked at $71K in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Hunter Associates Investment Management's 13F filing for Q2 2019, filed 8 Aug 2019.